Therapy Detail

Therapy Name Trastuzumab + Lapatinib
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Lapatinib Tykerb FMM EGFR Inhibitor (Pan) 38 HER2 (ERBB2) Antibody 25 Tykerb (lapatinib) reversibly inhibits ERBB2 (HER2) and EGFR, resulting in decreased downstream signaling and potentially leading to reduced tumor growth (PMID: 22477724). Tykerb (lapatinib) is FDA approved for ERBB2 (HER2)-positive breast cancer (FDA.gov).
Trastuzumab Herceptin Anti HER2 HER2 (ERBB2) Antibody 25 Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB2 amp colorectal cancer sensitive Trastuzumab + Lapatinib Preclinical - Pdx Actionable In a preclinical study, the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) treatment induced tumor regression in patient-derived colorectal cancer tumorgraft models harboring ERBB2 (HER2) amplification (PMID: 26296355). 26296355
ERBB2 S310Y colorectal cancer sensitive Trastuzumab + Lapatinib Preclinical Actionable In a preclinical study, Herceptin (trastuzumab) and Tykerb (lapatinib) combination treatment resulted in tumor regression in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863). 26243863
ERBB2 amp ERBB2 L755S Her2-receptor positive breast cancer resistant Trastuzumab + Lapatinib Preclinical - Cell culture Actionable In a preclinical study, expression of ERBB2 (HER2) L755S conferred resistance to Tykerb (lapatinib) plus Herceptin (trastuzumab) combination therapy in ESR1-positive/ERBB2 (HER2)-positive breast cancer cells with ERBB2 amplification in culture (PMID: 28487443). 28487443
ERBB2 amp stomach cancer sensitive Trastuzumab + Lapatinib Preclinical - Cell line xenograft Actionable In a preclinical study, the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) treatment induced tumor regression in ERBB2 (HER2)-amplified cell line xenograft models of gastric cancer (PMID: 26296355). 26296355
ERBB2 positive Her2-receptor positive breast cancer sensitive Trastuzumab + Lapatinib Phase II Actionable In a Phase II trial, Tykerb (lapatinib) and Herceptin (trastuzumab) combination treatment resulted in complete response in the breast in 10.6% (7/66) and minimal residual disease in 16.7% (11/66) of ERBB2-positive breast cancer patients 11 days after receiving the treatment (European Breast Cancer Conference; Mar 2016; Abstract #6LBA). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Trastuzumab + Lapatinib Clinical Study Actionable In a meta-analysis of six randomized clinical trials, Tykerb (lapatinib) and Herceptin (trastuzumab) combination treatment resulted in 13% absolute improvement in pathologic complete response rate in ERBB2 (HER2)-positive breast cancer patients compared to Herceptin (trastuzumab) single treatment (PMID: 27140927). 27140927
ERBB2 positive KRAS wild-type colorectal cancer sensitive Trastuzumab + Lapatinib Phase II Actionable In a Phase II clinical trial, 30% (8/27) of patients with ERBB2 (HER2)-positive KRAS wild-type colorectal cancer achieved an objective response and 44% (12/27) of patients had stable disease when treated with the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 27108243). 27108243
ERBB2 T798M breast cancer sensitive Trastuzumab + Lapatinib Preclinical - Cell line xenograft Actionable In a preclinical study, human breast cancer cell lines and cell line xenografts expressing ERBB2 T798M demonstrated sensitivity to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23948973). 23948973
Clinical Trial Phase Therapies Title Recruitment Status
NCT01160211 Phase III Trastuzumab + Lapatinib Letrozole Anastrozole Lapatinib Trastuzumab Exemestane A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer Active, not recruiting
NCT00968968 Phase III Trastuzumab Trastuzumab + Lapatinib Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone Completed
NCT02073487 Phase II Paclitaxel Trastuzumab emtansine + Lapatinib Trastuzumab + Lapatinib nab-paclitaxel Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel Active, not recruiting
NCT02213042 Phase II Trastuzumab + Lapatinib Trastuzumab Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer Active, not recruiting
NCT01273610 Phase II Trastuzumab + Lapatinib Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Metastatic Breast Cancer Active, not recruiting
NCT00790816 Phase I Lapatinib + Paclitaxel Lapatinib Trastuzumab + Lapatinib Lapatinib + Capecitabine Lapatinib + Letrozole Lapatinib + Oxaliplatin + Capecitabine Lapatinib + Gemcitabine Lapatinib + Docetaxel Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil Lapatinib + Irinotecan + Leucovorin + Fluorouracil Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents Completed
NCT01875666 Phase I Trastuzumab + Lapatinib Trastuzumab Pertuzumab Pertuzumab + Trastuzumab Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib Active, not recruiting